Sourcing high-purity PNC-27 online for laboratory research requires verifying lot-specific third-party analytical documentation. PNC-27 is a synthetic, membrane-active peptide engineered to selectively target membrane-bound HDM-2 on transformed cells, inducing rapid transmembrane pore formation and cell necrosis independent of p53 status in preclinical models.
Sourcing high-purity PNC-27 online for laboratory research requires verifying lot-specific third-party analytical documentation. PNC-27 is a synthetic, membrane-active peptide engineered to selectively target membrane-bound HDM-2 on transformed cells, inducing rapid transmembrane pore formation and cell necrosis independent of p53 status in preclinical models.
PNC-27 is a synthetic construct comprising a specific p53-derived HDM-2 binding domain coupled to a transmembrane-penetrating leader sequence derived from the antennapedia homeodomain (penetratin). The primary amino acid sequence corresponds to residues 12–26 of the human p53 protein (PPLSQETFSDLWKLL), fused at its carboxyl terminus to the 16-amino acid penetratin peptide (RQIKIWFQNRRMKWKK). This amphipathic structure allows PNC-27 to interact dynamically with lipid bilayers and target specific membrane-bound receptor complexes.
In basic biomedical research, PNC-27 serves as a key molecular tool for examining non-apoptotic cell death signaling. Unlike conventional cytotoxic agents that rely on intracellular enzymatic cascades or DNA damage pathways, PNC-27 engages target proteins localized directly on the cell surface. Investigators working with PNC-27 reference material analyze its conformational dynamics using circular dichroism and nuclear magnetic resonance (NMR) spectroscopy to understand how the peptide transitions from a random coil in aqueous solution to an alpha-helical structure upon lipid membrane insertion.
The primary mechanism under investigation for PNC-27 centers on its capacity to selectively bind HDM-2 (human double minute 2) protein expressively presented on the outer cell membrane of cancer cells. In untransformed, healthy somatic cells, HDM-2 functions predominantly as an intracellular E3 ubiquitin ligase localized within the nucleus and cytoplasm. However, preclinical assays demonstrate that many transformed tumor cell lines exhibit aberrant localization of HDM-2 to the plasma membrane.
Upon binding membrane-bound HDM-2, the hydrophobic alpha-helical domain of PNC-27 inserts directly into the lipid bilayer. Structural modeling and electron microscopy indicate that multiple PNC-27 monomers oligomerize within the membrane microdomain, generating transmembrane pores measuring approximately 1 to 2 nanometers in diameter. This pore formation causes rapid membrane dissipation, loss of osmotic integrity, influx of extracellular ions, and subsequent cell lysis (membranolytic necrosis). Because this lytic event occurs directly at the cell surface, the cytotoxic effect operates independently of functional p53 expression, transcription factors, or caspase activation cascades.
In vitro evaluations across diverse oncology research lines—including pancreatic carcinoma, glioblastoma, breast adenocarcinoma, and acute myelogenous leukemia—indicate that PNC-27 exhibits selective cytotoxicity toward malignant cells while sparing adjacent untransformed control cells. In these tissue culture assays, cell viability assays (e.g., LDH release, MTT, and trypan blue exclusion) demonstrate rapid cell lysis occurring within 30 to 120 minutes of peptide exposure.
In animal model systems, xenograft preclinical trials have examined localized and systemic administration of PNC-27. In rodent studies evaluating subcutaneous tumor implants, intratumoral infusion of PNC-27 led to visible tumor necrosis without significant systematic organ toxicity or histopathological changes in healthy tissue. Researchers studying p53-HDM2 pathway research frequently utilize PNC-27 to differentiate between nuclear ubiquitination mechanics and surface-bound receptor interactions in solid tumor microenvironments.
To contextualize PNC-27 within the broader landscape of oncology research compounds, scientists frequently evaluate it alongside related structural analogs and cell-penetrating constructs. Understanding these molecular differences helps research teams design targeted assays across our full catalog of synthetic peptides.
PNC-28 is a closely related peptide containing p53 residues 17–26 connected to the same penetratin leader sequence. Comparative cell culture assays show that both PNC-27 and PNC-28 research literature exhibit similar HDM-2 binding affinity and membranolytic pore-forming characteristics, though minor variations in secondary structure stability exist between the two constructs. Additionally, researchers contrast these HDM-2-targeting peptides with classical cationic cell-penetrating peptides like TAT or polyarginine, which cross lipid membranes without selectively inducing pore-mediated cell lysis.
When procuring PNC-27 online for laboratory experiments, institutional buyers must rigorously evaluate supplier manufacturing quality, analytical standards, and verification procedures. Synthetic peptides containing hydrophobic residues and leader sequences can present synthesis challenges, including truncated sequences, deletion sequences, and incomplete deprotection during solid-phase peptide synthesis (SPPS).
To ensure reproducible experimental outcomes, research facilities should only utilize PNC-27 validated by comprehensive, lot-specific Certificate of Analysis (COA) documentation. Key parameters to demand prior to acquisition include high-performance liquid chromatography (HPLC) demonstrating ≥98% purity, electrospray ionization mass spectrometry (ESI-MS) confirming exact molecular weight, and quantitative chromogenic LAL assays verifying low endotoxin limits (<0.01 EU/μg). Sourcing from facilities operating under ISO 17025 accredited quality management guarantees that analytical data reflects true physical sample characteristics.
PNC-27 is supplied as a lyophilized (freeze-dried) solid cake or powder to preserve molecular stability during transit and storage. Proper reconstitution in a sterile, controlled environment is critical to prevent aggregation, sequence degradation, or premature precipitation prior to assay execution.
For standard cell culture and in vitro biochemical assays, researchers typically reconstitute PNC-27 in sterile, deionized laboratory-grade water or low-salt buffer such as phosphate-buffered saline (PBS, pH 7.4). If dissolution proves difficult due to hydrophobic domain interactions, initial solvation in a minimal volume of dimethyl sulfoxide (DMSO, ultra-pure assay grade) followed by dilution into aqueous buffer solution is recommended. Vigorous vortexing or sonication should be minimized to avoid mechanical shearing or surface denaturing; gentle swirling or inversion is preferred.
Lyophilized PNC-27 should be stored at -20°C or -80°C in a desiccated environment protected from light exposure upon arrival at the research facility. Under these conditions, the un-reconstituted peptide maintains chemical integrity for 24 to 36 months.
Once reconstituted into an aqueous solution, PNC-27 exhibits reduced shelf-life due to potential hydrolysis and peptide aggregation over time. Reconstituted stock solutions should be divided into single-use experimental aliquots to prevent repeated freeze-thaw cycles, which compromise helical peptide conformation. Aliquoted solutions stored at -80°C remain stable for up to 3 to 6 months, while working solutions kept at 4°C should be utilized within 24 to 48 hours for optimal assay accuracy.
PX1 Research supports academic institutions, biotechnology entities, and contract research organizations (CROs) by providing fully documented, domestic-manufactured research peptides. Every batch of PNC-27 is synthesized in the USA within state-of-the-art GMP-compliant facilities and tested by independent ISO 17025 accredited laboratories.
Principal investigators and lab procurement managers can review complete analytical spectra and access detailed documentation through our PX1 Research Library. For larger experimental series requiring custom synthesis batches or volume pricing, institutional clients can establish a streamlined direct fulfillment account via our wholesale account program. All standard online orders ship same-day Monday through Friday from our primary distribution hubs in California and Arizona.
What is PNC-27 and what is its primary molecular function in research?
PNC-27 is a synthetic, membrane-active peptide composed of a p53 HDM-2 binding domain coupled to a penetratin leader sequence. In preclinical research, it is studied for its ability to bind HDM-2 on the plasma membrane of cancer cells and induce cell lysis via pore formation.
How does PNC-27 cause cell death in preclinical models?
Preclinical studies demonstrate that PNC-27 binds to surface-expressed HDM-2 proteins, inserts into the lipid bilayer, oligomerizes, and forms transmembrane pores. This leads to osmotic swelling and rapid non-apoptotic necrosis, independent of p53 genetic status.
What purity levels are required for experimental PNC-27?
For reliable in vitro and cell culture research, PNC-27 should possess a chromatographic purity of ≥98% as determined by RP-HPLC, with sequence identity confirmed via ESI-MS mass spectrometry and endotoxin levels tested below 0.01 EU/μg.
How should lyophilized PNC-27 be stored upon receipt?
Lyophilized PNC-27 should be kept in a desiccated container at -20°C or -80°C, protected from light. Stored under sub-zero conditions, the un-reconstituted peptide remains stable for up to 2 to 3 years.
What is the recommended reconstitution procedure for PNC-27?
Reconstitute using sterile research-grade water or PBS (pH 7.4). For challenging solubility at higher concentrations, a minimal volume of sterile DMSO can be used initially, followed by dilution into standard aqueous assay buffer.
Does PNC-27 affect untransformed normal cells in tissue culture?
In vitro studies consistently show that PNC-27 displays selective cytotoxicity toward cancer cells while leaving non-transformed normal cells intact, primarily because normal cells lack significant HDM-2 expression on their outer cell membranes.
How does PNC-27 differ from PNC-28?
PNC-27 contains p53 amino acids 12–26, whereas PNC-28 contains p53 amino acids 17–26. Both are attached to the same penetratin leader peptide and share a similar HDM-2-targeting, pore-forming mechanism in cancer cell models.
Where is PX1 Research PNC-27 manufactured and shipped from?
PX1 Research peptides are manufactured in the USA within GMP-compliant facilities. Orders are verified by independent ISO 17025 laboratories and shipped same-day (Monday through Friday) from distribution centers in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.